Q-omics provides the consensus-scored BOC profile across patient tissues and cancer cell-line models. BOC expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, BOC is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, BOC RNA expression shows 18,013 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, KICH, and THYM as cancer lineages where BOC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BOC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BOC survival associations across molecular data types. BOC RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BOC RNA expression–survival associations across cancer types. High BOC expression shows unfavorable associations in BLCA, but favorable associations in HNSC, LIHC, MESO, KIRC and UCS. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for BOC RNA expression.
This table summarizes BOC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for BOC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BOC shows lower tumor expression in KICH, HNSC, BLCA, THCA and UCEC and higher tumor expression in LIHC. The KICH box plot shows higher BOC RNA expression in normal versus tumor tissue (log2 FC = −2.093, t-test p < 0.001).
This table shows molecular features associated with BOC in patient tissues and cancer cell lines. In patient samples, BOC shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, BOC RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BREAST.
